| Orion Minerals Ltd (ORN) ORDINARY FULLY PAID |
Materials |
$277 |
Quarterly Activities Report
|
30 Jan 2026 8:29AM |
$0.034 |
$0.034 |
fallen by
0%
|
|
ORN - Price-sensitive ASX Announcement
Full Release
Key Points
- Completion of due diligence for Glencore offtake and financing.
- Operational readiness and value engineering at Prieska Copper Zinc Mine.
- First concentrate from PCZM targeted by Christmas 2026.
- Exploration advancements at Okiep Copper Project.
- No safety incidents reported; high standards of environmental compliance maintained.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Enlitic Inc (ENL) CHESS DEPOSITARY INTERESTS 1:1 US PROHIBITED |
Health Care |
$7 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
30 Jan 2026 8:29AM |
$0.014 |
$0.009 |
fallen by
35.71%
|
|
ENL - Price-sensitive ASX Announcement
Full Release
Key Points
- Record total contract value of A$4.3m in Q4 FY25.
- 16 new client agreements executed in Q4 FY25.
- Completed capital raise of A$2.6m; additional A$5.4m subject to approval.
- Net operating cash outflow of US$3.3m for the quarter.
- Cash balance of US$2.57m at the end of December 2025.
- Implemented cost reduction measures for US$2.5m in annual savings.
- Revenue impacted by expanded project scopes.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| NOVONIX Limited (NVX) ORDINARY FULLY PAID |
Information Technology |
$288 |
Application for quotation of securities - NVX
|
30 Jan 2026 8:29AM |
$0.390 |
$0.335 |
fallen by
14.10%
|
|
| Origin Energy Limited (ORG) ORDINARY FULLY PAID |
Utilities |
$21,018 |
December 2025 Quarterly Report
|
30 Jan 2026 8:28AM |
$11.800 |
$12.200 |
risen by
3.39%
|
|
| Amplia Therapeutics Limited (ATX) ORDINARY FULLY PAID |
Health Care |
$64 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
30 Jan 2026 8:28AM |
$0.130 |
$0.125 |
fallen by
3.85%
|
|
ATX - Price-sensitive ASX Announcement
Full Release
Key Points
- Amplia ended the December 2025 quarter with AUD 31.5 million in cash.
- Net operating cash inflows for the quarter were AUD 2.4 million.
- Received AUD 3.8 million from government grants and tax incentives.
- Operating outflows included AUD 0.9 million for staff and administration costs.
- ACCENT trial showed a 35% response rate with narmafotinib.
- AMPLICITY trial initiated to explore narmafotinib with FOLFIRINOX.
- Positive FDA feedback on dosage optimization for narmafotinib.
- Granted a key patent for narmafotinib.
- Listed on the US-based OTCQB Venture Market.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Helia Group Limited (HLI) ORDINARY FULLY PAID |
Financials |
$1,583 |
2025 Full Year Results Release Date
|
30 Jan 2026 8:28AM |
$5.780 |
$5.810 |
risen by
0.52%
|
|
| RMA Global Limited (RMY) ORDINARY FULLY PAID |
Communication Services |
$30 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
30 Jan 2026 8:28AM |
$0.049 |
$0.045 |
fallen by
8.16%
|
|
RMY - Price-sensitive ASX Announcement
Full Release
Key Points
- Net operating cash outflow of $592,000 in Q2 FY26.
- Cash receipts from customers totaled $5.8 million, an 11% increase from Q2 FY25.
- Organic cash receipts grew by 3%, excluding Curated Social.
- Operational cash payments increased by 25% compared to Q2 FY25.
- RMA Global Limited rebranded to Renowned.
- US subscription revenue rose by 38% year-on-year.
- ANZ revenue grew by 5% due to new multi-year partnerships.
- Cash on hand as of 31 December 2025 was $3.1 million.
- Focus on expanding US market with multi-year brokerage deals.
- Payments to related parties totaled $114,000, related to director fees.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Felix Gold Limited (FXG) ORDINARY FULLY PAID |
Materials |
$162 |
Quarterly Activities and Cashflow Reports
|
30 Jan 2026 8:28AM |
$0.385 |
$0.330 |
fallen by
14.29%
|
|
FXG - Price-sensitive ASX Announcement
Full Release
Key Points
- $18 million institutional placement completed
- Blair Way appointed as Non-Executive Director
- Significant expenditure on exploration and project studies in Alaska
- Targeting metal production in H2 2026
- Submitted applications for DOE pilot processing facility and exploration technology
- Strengthened executive and non-executive governance
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| NeuroScientific Biopharmaceuticals Ltd (NSB) ORDINARY FULLY PAID |
Health Care |
$38 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
30 Jan 2026 8:27AM |
$0.135 |
$0.115 |
fallen by
14.81%
|
|
NSB - Price-sensitive ASX Announcement
Full Release
Key Points
- StemSmart™ Special Access Program for Crohn's Disease is advancing.
- Phase 2 Clinical Trial preparation is underway with real-world clinical data.
- Appointment of a Clinical & Scientific Advisory Board to support development.
- Technology transfer to Q-Gen for manufacturing readiness is progressing.
- Strong financial position with cash and cash equivalents approximately $6.4 million.
- Net cash outflow from operating activities was $532k for the quarter.
- Research and development payments totaled approximately $315k.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Lotus Resources Limited (LOT) ORDINARY FULLY PAID |
Energy |
$574 |
Quarterly Activities and Cash Flow Reports - December 2025
|
30 Jan 2026 8:27AM |
$0.225 |
$2.110 |
risen by
837.78%
|
|
LOT - Price-sensitive ASX Announcement
Full Release
Key Points
- Kayelekera Uranium Mine's production impacted by sulphuric acid supply issues.
- Production resumed mid-January with the best run time since restart.
- Acid plant rebuild on schedule for March 2026 commissioning.
- Uranium deliveries and strategy focus on market-linked pricing.
- Successful metallurgical testwork at Letlhakane could reduce acid consumption by 70%.
- Closing cash balance A$56.2M, exploring additional financing options.
- No Lost Time Injuries recorded, targeting two million LTI-free person days.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| ResMed Inc. (RMD) CDI 10:1 FOREIGN EXEMPT NYSE |
Health Care |
$21,074 |
Dividend/Distribution - RMD
|
30 Jan 2026 8:27AM |
$36.400 |
$36.300 |
fallen by
0.27%
|
|
| Regis Healthcare Limited (REG) ORDINARY FULLY PAID |
Health Care |
$1,947 |
Initial Director's Interest Notice
|
30 Jan 2026 8:27AM |
$6.610 |
$6.440 |
fallen by
2.57%
|
|
| Far Limited (FAR) ORDINARY FULLY PAID |
Energy |
$46 |
Quarterly Activities Report and Appendix 5B
|
30 Jan 2026 8:27AM |
$0.455 |
$0.500 |
risen by
9.89%
|
|
FAR - Price-sensitive ASX Announcement
Full Release
Key Points
- FAR Limited reported a cash balance of US$1.9 million at the end of the December 2025 quarter.
- The company entered into a settlement agreement with Woodside Energy, paying US$6,029,899 concerning the RSSD Project claim.
- FAR Limited has a contingent payment agreement with Woodside Energy, which could give a maximum value of US$55 million, based on oil price and production conditions.
- The contingent payment is linked to the Sangomar Project in Senegal, and the payment terminates on the earliest of 31 December 2027 or when US$55 million is reached.
- The company has no outstanding loans or unused financing facilities as of the end of the quarter.
- Aggregate payments to related parties and their associates during the quarter were US$49,000, mainly for Non-Executive Director remuneration.
- The company forecasts having sufficient cash for 55.20 quarters based on current available funding and expenditures.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Magnum Mining and Exploration Limited (MGU) ORDINARY FULLY PAID |
Materials |
$19 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
30 Jan 2026 8:27AM |
$0.005 |
$0.006 |
risen by
20%
|
|
MGU - Price-sensitive ASX Announcement
Full Release
Key Points
- Commencement of two drilling programs at Palmares and Azimuth REE Projects.
- Acquisition of the Wet Mountains REE Project in Colorado.
- Leach testing at Feirinha Prospect confirmed high-value magnet feedstock potential.
- Oversubscribed A$7.0 million capital raise completed.
- Execution of binding MoU with HomeRun Resources for REE separation technology.
- Continued evaluation of a critical minerals processing hub in Nevada.
- Quarter-end cash and cash equivalents at $5.862 million.
- Estimated funding available for 4.97 quarters.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Murray Cod Australia Limited (MCA) ORDINARY FULLY PAID |
Consumer Staple |
$56 |
Quarterly Activities/Appendix 4C Cash Flow Report - Q2 FY26
|
30 Jan 2026 8:27AM |
$1.045 |
$0.530 |
fallen by
49.28%
|
|
MCA - Price-sensitive ASX Announcement
Full Release
Key Points
- Cash receipts from customers totaled $3,650,000 for Q2 FY26.
- Total cash outflows from operating activities amounted to $5,341,000.
- Sales volume increased but faced demand challenges for larger fish sizes.
- Net cash from financing activities was $6,162,000.
- MCA is expanding market presence in Southeast Asia.
- Company biomass reached 2,787 tonnes by the end of December 2025.
- Production infrastructure expansion is ongoing with full pond utilization expected.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Dyno Nobel Limited (DNL) ORDINARY FULLY PAID |
Materials |
$5,926 |
Update - Notification of buy-back - DNL
|
30 Jan 2026 8:26AM |
$3.560 |
$3.330 |
fallen by
6.46%
|
|
| ResMed Inc. (RMD) CDI 10:1 FOREIGN EXEMPT NYSE |
Health Care |
$21,074 |
Resmed Announces Results for the Second Quarter of FY2026
|
30 Jan 2026 8:26AM |
$36.400 |
$36.300 |
fallen by
0.27%
|
|
RMD - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased by 11% to $1.422 billion.
- Non-GAAP gross profit margin improved to 62.3%.
- Net income rose to $392.6 million, an increase from $344.6 million.
- Diluted earnings per share increased to $2.68.
- Strong sales performance in U.S., Canada, and Latin America.
- Growth driven by devices and masks sales.
- Operational efficiency improved despite global challenges.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Murray Cod Australia Limited (MCA) ORDINARY FULLY PAID |
Consumer Staple |
$56 |
Appointment of Non-Executive Director - Peter McCluskey
|
30 Jan 2026 8:26AM |
$1.045 |
$0.530 |
fallen by
49.28%
|
|
| Bannerman Energy Ltd (BMN) ORDINARY FULLY PAID |
Energy |
$899 |
Change in substantial holding - MMAM
|
30 Jan 2026 8:25AM |
$4.700 |
$4.330 |
fallen by
7.87%
|
|
| NewPeak Metals Limited (NPM) ORDINARY FULLY PAID |
Materials |
$8 |
Quarterly Activities and Cashflow Reports
|
30 Jan 2026 8:25AM |
$0.027 |
$0.023 |
fallen by
14.81%
|
|
NPM - Price-sensitive ASX Announcement
Full Release
Key Points
- Net cash outflow from operating activities driven by staff and corporate costs.
- Investing activities include acquisition payments related to exploration permits.
- End of quarter cash position is approximately $2.49 million.
- Las Opeñas drilling approval significantly impacts future exploration plans.
- No exploration activities planned at George River and Treuer Range projects in the near term.
- Exploration Manager visited Cachi Gold Project; focus is shifting to Las Opeñas.
- Payments to related parties include executive and non-executive director fees.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Fleetwood Limited (FWD) ORDINARY FULLY PAID |
Consumer Discretionary |
$248 |
Appointment of New Chief Executive Officer
|
30 Jan 2026 8:25AM |
$2.850 |
$2.680 |
fallen by
5.96%
|
|
FWD - Price-sensitive ASX Announcement
Full Release
Key Points
- Appointment of Andrea Pidcock as CEO effective February 2, 2026.
- Extensive leadership experience in industrial and operational sectors.
- Former executive roles at Rio Tinto, Optus, and Boral.
- Focus on EBIT improvement and operational enhancements.
- Andrea's leadership expected to drive growth in construction methods.
- Annual remuneration of $700,000 with incentive plans.
- Executive Chairman John Klepec to return as non-executive director.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| AdAlta Limited (1AD) ORDINARY FULLY PAID |
Health Care |
$8 |
Quarterly Appendix 4C and Activities Report
|
30 Jan 2026 8:25AM |
$0.005 |
$0.003 |
fallen by
40%
|
|
1AD - Price-sensitive ASX Announcement
Full Release
Key Points
- AdAlta launched 'East to West' strategy with Shanghai Cell Therapy Group.
- Development of CAR-T therapy targeting mesothelioma.
- Raised $2.8 million through private placements.
- Received $0.93 million R&D Tax Incentive refund.
- Cash balance increased to $1.58 million by end of quarter.
- Significant expenditures in R&D and staff costs.
- Strengthened financial position with capital raises and repayments.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| James Hardie Industries Plc (JHX) CHESS DEPOSITARY INTERESTS 1:1 |
Materials |
$15,070 |
Notification regarding unquoted securities - JHX
|
30 Jan 2026 8:25AM |
$33.730 |
$35.010 |
risen by
3.79%
|
|
| Fluence Corporation Limited (FLC) ORDINARY FULLY PAID |
Utilities |
$91 |
Fluence Q4 2025 Update Investor Presentation
|
30 Jan 2026 8:25AM |
$0.089 |
$0.080 |
fallen by
10.11%
|
|
FLC - Price-sensitive ASX Announcement
Full Release
Key Points
- Strong financial growth with Q4 and FY 2025 revenue of $26.0M and $78.4M, respectively.
- Significant backlog increase to $74.8M with core business units' backlog growing by 43.8%.
- Record new order bookings for Q4 2025 and FY 2025.
- Strategic shift to high-margin Smart Product Solutions and Recurring Revenue segments.
- Completion of CEO/CFO succession and strategic realignment.
- Notable projects in Ivory Coast, Saudi Arabia, Argentina, and Italy.
- Enhancements in Municipal Water & Wastewater and Industrial Wastewater & Biogas segments.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Proteomics International Laboratories Ltd (PIQ) ORDINARY FULLY PAID |
Health Care |
$62 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
30 Jan 2026 8:25AM |
$0.570 |
$0.375 |
fallen by
34.21%
|
|
PIQ - Price-sensitive ASX Announcement
Full Release
Key Points
- Proteomics International Laboratories Ltd reported cash receipts from customers totaling $127,000 for the current quarter and $1,991,000 year-to-date.
- Research and development payments were $965,000 for the current quarter and $1,996,000 year-to-date.
- The company received government grants and tax incentives amounting to $2,687,000.
- There was a net cash outflow from operating activities of $182,000 for the quarter, and $951,000 year-to-date.
- Investing activities resulted in a net cash outflow of $1,986,000 for the current quarter and $2,059,000 year-to-date.
- Financing activities yielded a net cash outflow of $182,000 for the quarter and $358,000 year-to-date.
- Cash and cash equivalents decreased from $10,019,000 at the beginning of the quarter to $7,669,000 by the end.
- Payments to related parties during the quarter totaled $194,000, which relate to remuneration for Directors.
- The company has no loan facilities or credit standby arrangements available.
- Proteomics International Laboratories Ltd estimates 42 quarters of funding available with the current cash flow.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
